Effectiveness of Human Papillomavirus (HPV) Vaccine against HPV16/18-positive High-grade Cervical Lesions

Julia Warner Gargano, PhD

Epidemiologist Centers for Disease Control and Prevention Atlanta, Georgia, USA



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases



• No financial relationships or conflicts of interest to disclose





Background

- Randomized controlled trials demonstrated high efficacy of HPV vaccines against high-grade cervical lesions
- To date, real-world vaccine effectiveness (VE) has been demonstrated for HPV prevalence, anogenital warts, and highgrade cervical lesions

- Variety of study designs and populations
- Few studies have evaluated VE against HPV type-specific cervical lesions



HPV-IMPACT: Detection of cervical cancer precursors and associated HPV types



- HPV Vaccine Impact Monitoring Program (HPV-IMPACT)
- Part of Emerging Infections Program
- Active surveillance for cervical precancers in women <a>>18 years in catchment area
- Determine HPV types in lesions from subset of women 18–39 years, vaccine history
- Estimate annual cervical cancer screening

AS€P

Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

Case definition

CIN2+: cervical intraepithelial neoplasia (CIN) grades 2, 3, 2/3, and adenocarcinoma in situ (AIS)

- Woman aged ≥18 years
- Resident of catchment area
- Year 2008 or later





Data elements

All cases

- Demographics (date of birth, race, insurance)
- Diagnosis
- Additional data elements for cases aged 18–39 years
 - Cervical cancer screening event that led to diagnosis
 - History of HPV vaccination
 - Residual tissue specimen obtained for HPV typing






HPV typing

- At each surveillance site
 - Tissue blocks cut per CDC protocol
 - Specimens sent to CDC
- At CDC HPV laboratory
 - Slides reviewed to confirm representative lesion present
 - HPV typing: 37 HPV types







Objective

- To estimate vaccine effectiveness against vaccine-type CIN2+ by timing of vaccination relative to outcome ascertainment
 - Interval between vaccination and screening test that led to CIN2+ diagnosis, or vaccination-to-trigger Pap interval





Inclusion criteria

- Diagnosed with CIN2+ in 2008–2014
- Age-eligible for vaccination
- Known date of screening test that led to CIN2+ diagnosis
- Known date of HPV vaccination
- Valid HPV typing result





Vaccination history: vaccinated, unvaccinated, unknown

- Verified through medical records and vaccine registries
- Vaccinated, ≥1 dose of HPV vaccine:
 - History of vaccination noted in medical record or registry
 - Started vaccine series at ages 9-26 years
- Unvaccinated:
 - Medical record documented lack of HPV vaccination
 - Continuously enrolled in insurance plan and no claim

ASCCP2018 Annual Meeting

Unknown: excluded from analysis



Time between vaccination and outcome assessment

- HPV vaccine must be administered prior to infection to be effective
- It can take years after infection for CIN2+ lesions to develop
- With longer interval, higher likelihood that vaccination occurred prior to infection responsible for CIN2+ lesion
 - We evaluated intervals <1 month/unvaccinated, 1–11 months, 12–23 months, 24–35 months, 36–47 months, and ≥48 months



Vaccine effectiveness (VE) design

- Indirect cohort, aka test-negative design or Broome method
- Variation on case-control study that uses only cases of disease
 - "Cases": CIN2+ with vaccine type (HPV16/18 positive)
 - "Controls": CIN2+ without vaccine type (HPV16/18 negative)





VE analysis

Logistic regression

Estimate odds ratio by vaccination-to-trigger Pap interval

ASCCP2018 Annual Meeting

- Adjust for site, race, insurance
- VE = 1 aOR

Evaluated VE stratified by birth cohort group

- Tested statistical interaction
- Younger cohort, born 1987–1995
- Older cohort, born 1979–1986



Interval between vaccination and trigger Pap (N=3310)

Interval	Ν	%
Vaccinated <1 month before trigger or no vaccine	2374	71.7
Never vaccinated	1801	54.4
Vaccinated after trigger	544	0.9
Vaccinated <1 month before trigger	29	22.9
Vaccinated ≥1 month before trigger	936	28.3
1-11 months	170	5.1
12-23 months	195	5.9
24-35 months	146	4.4
36-47 months	133	4.0
≥48 months	292	8.8



Characteristics of CIN2+ cases by vaccination history

Characteristic	All %	Vaccinated %	Unvaccinated %	P-Value
Diagnosis years				<0.01
2008-2010	52	38	57	
2011-2014	48	62	43	
Age at diagnosis (years)				<0.01
18-20	7	8	6	
21-24	40	47	37	
25-29	43	41	43	
30-34	11	4	14	
Birth cohort group				<0.01
1987-1994	35	50	29	
1979-1986	65	50	71	



Characteristics of CIN2+ cases by vaccination history

Characteristic	All %	Vaccinated %	Unvaccinated %	P-Value
Diagnosis				<0.01
CIN2	55	60	53	
CIN2/3	14	14	15	
CIN3/AIS	31	26	32	
Race/ethnicity				0.09
Non-Hispanic White	57	62	56	
Non-Hispanic Black	17	17	16	
Hispanic	10	8	11	
Asian	3	3	2	
Other	13	12	14	
Insurance				<0.01
Private	55	62	53	
Public	25	19	27	
None/other/missing	20	19	21	



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

Vaccine effectiveness by vaccination-to-trigger interval

Months before screening	Cases (16/18+) N (%)	Controls (16/18-) N (%)	OR	95% CI	aOR*	95% CI	VE
<1 mo. or no vaccine	1228 (78.0)	1146 (68.8)	1.00		1.00		
1-11 months	94 (6.0)	76 (4.4)	1.15	(0.84-1.58)	1.13	(0.83-1.56)	
12-23 months	91 (5.8)	104 (6.0)	0.82	(0.61-1.09)	0.77	(0.57-1.04)	
24-35 months	55 (3.5)	91 (5.2)	0.56	(0.40-0.80)	0.56	(0.40-0.80)	44%
36-47 months	40 (2.6)	93 (5.3)	0.40	(0.28-0.59)	0.39	(0.27-0.58)	61%
48+ months	61 (3.9)	231 (13.3)	0.25	(0.18-0.33)	0.24	(0.18-0.33)	76%

*Adjusted for insurance, race, site.



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

Differences by birth cohort group

Descriptor	Born 1987-1994 "Younger cohort"	Born 1979-1986 "Older cohort"
Ages at diagnosis with CIN2+	18-26 years	22-34 years
Opportunity to be vaccinated	12-26 years	20-26 years
Median [IQR] age at vaccination	19 [17-25] years	23 [22-25] years
% vaccinated	20%	11%



Vaccine effectiveness by vaccination-to-trigger interval, stratified by birth cohort

Vounger Cohart (harn 1087-1005)*

	tounger conort (born 1987-1995).		Older Couort (boln 1979-1986).		
Months before screening	aOR (95% CI)**	Vaccine effectiveness	aOR (95% CI)**	Vaccine effectiveness	
<1 mo. or no vaccine	1.00		1.00		
1-11 months	0.85 (0.53-1.36)		1.46 (0.94-2.25)		
12-23 months	0.69 (0.43-1.10)		0.84 (0.57-1.23)		
24-35 months	0.53 (0.31-0.89)	47%	0.59 (0.37-0.94)	41%	
36-47 months	0.26 (0.14-0.48)	74%	0.55 (0.33-0.90)	45%	
48+ months	0.16 (0.11-0.25)	84%	0.41 (0.27-0.63)	59%	

*P-value for cohort x vaccination interaction = 0.008. **Adjusted for insurance, race, site.



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

ASCCP2018 Annual Meeting

Older Cohert (here 1070 1096)*

Summary of vaccine effectiveness findings

- Significant effectiveness against HPV16/18 positive CIN2+ when vaccine given at least 24 months before screening
 - 44% at 24-35 months
 - 61% at 36-47 months
 - 76% at ≥48 months
- Younger cohort had higher VE than older cohort
 - Younger cohort born 1987-1994: VE range 47-84% (24-48+ months)

ASCCP2018 Annual Meeting

Older cohort born 1979-1986: VE range 41-59% (24-48+ months)



Limitations

- Many women missing complete vaccination history
- Few women vaccinated at recommended age





Conclusion

- Vaccine effectiveness against HPV16/18 positive CIN2+ significant when vaccine administered at least 24 months before CIN2+ diagnosis
- Higher effectiveness in younger cohort and with longer intervals consistent with high efficacy seen in trials in per protocol populations
- Affirms importance of vaccination at younger ages, before exposure to HPV

ASCCP2018 Annual Meeting

Continued monitoring needed



Acknowledgements

- California EIP
 - Ina Park
 - Erin Whitney
 - Ashley Williamson
 - Deanna Fink
 - Kayla Saadeh
- Connecticut EIP
 - Linda Niccolai
 - Monica Brackney
 - Jim Meek
 - Kyle Higgins
 - Lynn Sosa

Tennessee EIP

- Marie Griffin
- Deepthi Pemmaraju
- Sheelah Iyengar
- Stephanie Allen

Oregon EIP

- Sean Schafer
- Melissa Powell
- Nasreen Abdullah
- Rob Laing
- Sara Ehlers
- New York EIP
 - Nana Bennett
 - Mary Scahill
 - Christina Felsen
 - Gary Hollick
 - Marina Feiler
- Participating local labs and partners

 Centers for Disease Control and Prevention (CDC)

> Angela Cleveland Becky Dahl Susan Hariri Michelle Johnson Jones Lauri Markowitz Patrick McKibben Troy Querec Martin Steinau Beth Unger



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases